In contrast, Austen et al. demonstrated inferior OS and treatment-free survival in patients with ATM mutations [18], while Nadeu et al. identified ATM mutations, irrespective of del(11q), as a biomarker of shorter time-to-first-treatment (TTFT) but not OS in patients with CLL [4, 19]. This evidence concerns the gene ATM and B-cell chronic lymphocytic leukemia.